Author + information
- Received October 5, 2017
- Revision received December 31, 2017
- Accepted January 2, 2018
- Published online April 30, 2018.
- aDepartment of Genetics, Stanford University, Stanford, California
- bDepartment of Medicine, Stanford University, Stanford, California
- cStanford Center for Inherited Cardiovascular Disease, Stanford University, Stanford, California
- ↵∗Address for correspondence:
Dr. Euan A. Ashley, Stanford Center for Inherited Cardiovascular Disease, Stanford University, 300 Pasteur Drive, CVRB Falk, Mail Code 5406, Stanford, California 94305.
Precision medicine strives to delineate disease using multiple data sources—from genomics to digital health metrics—in order to be more precise and accurate in our diagnoses, definitions, and treatments of disease subtypes. By defining disease at a deeper level, we can treat patients based on an understanding of the molecular underpinnings of their presentations, rather than grouping patients into broad categories with one-size-fits-all treatments. In this review, the authors examine how precision medicine, specifically that surrounding genetic testing and genetic therapeutics, has begun to make strides in both common and rare cardiovascular diseases in the clinic and the laboratory, and how these advances are beginning to enable us to more effectively define risk, diagnose disease, and deliver therapeutics for each individual patient.
Ms. Dainis has received support from the National Science Foundation Graduate Research Fellowship Program and FDA project grant HHSF223201610115C Dr. Ashley is supported by National Institutes of Health (NIH) U24 award 1U24EB023674-01, NIH U01 award 1U01HG007708, and Food and Drug Administration project grant HHSF223201610115C.
Dr. Ashley is a Founder of Personalis and DeepCell, Inc.; and an advisor for SequenceBio and Genome Medical. Ms. Dainis has reported that she has no relationships relevant to the contents of this paper to disclose.
All authors attest they are in compliance with human studies committees and animal welfare regulations of the authors’ institutions and Food and Drug Administration guidelines, including patient consent where appropriate. For more information, visit the JACC: Basic to Translational Science author instructions page.
- Received October 5, 2017.
- Revision received December 31, 2017.
- Accepted January 2, 2018.
- 2018 The Authors
- Central Illustration
- Lessons From Precision Medicine in Oncology and Cystic Fibrosis
- Clinical Applicability of Genetic Testing in CVD and Precision Medicine
- Spotlight on Precision Medicine in a Rare CVD: LQTS
- Spotlight on Precision Medicine in a Common CVD: CAD and Cardiovascular Risk Scores
- FH: How Our Understanding of Rare Variants Can Improve Treatment Precision in Common Disease
- Tackling CVD by Correcting Disease-Associated Mutations: CRISPR and the Future of Genetic Precision Medicine
- iPSCs and Precision Medicine: Basic Research at the Individual Level
- Genotype-Guided Warfarin Dosing: A Note on the Importance of Cardiovascular Precision Medicine Studies Across Populations